Advanced search
Publication Cover
Immunotherapy Volume 4, 2012 - Issue 11
Submit an article Journal homepage
310
Views
0
CrossRef citations to date
0
Altmetric
Review

Cancer-Associated Fibroblasts as Targets for Immunotherapy

Sunitha Kakarla1 Center for Cell & Gene Therapy, Texas Children‘s Hospital, The Methodist Hospital, Baylor College of Medicine, 1102 Bates Street, Suite 1770, Houston, TX77030, USA;2 Texas Children‘s Cancer Center, Texas Children‘s Hospital, Baylor College of Medicine, Houston, TX, USA;3 Interdepartmental Program in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, TX, USAView further author information
,
Xiao-Tong Song1 Center for Cell & Gene Therapy, Texas Children‘s Hospital, The Methodist Hospital, Baylor College of Medicine, 1102 Bates Street, Suite 1770, Houston, TX77030, USA;2 Texas Children‘s Cancer Center, Texas Children‘s Hospital, Baylor College of Medicine, Houston, TX, USA;5 Pathology & Immunology, Baylor College of Medicine, Houston, TX, USAView further author information
&
Stephen Gottschalk1 Center for Cell & Gene Therapy, Texas Children‘s Hospital, The Methodist Hospital, Baylor College of Medicine, 1102 Bates Street, Suite 1770, Houston, TX77030, USA;2 Texas Children‘s Cancer Center, Texas Children‘s Hospital, Baylor College of Medicine, Houston, TX, USA;3 Interdepartmental Program in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, TX, USA;5 Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA;4 Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.Correspondence[email protected]
View further author information
Pages 1129-1138 | Published online: 29 Nov 2012

References

  • Paget S . The distribution of secondary growth in cancer of the breast. Lancet1 , 571–573 (1889).
  • Mueller MM , FusenigNE. Friends or foes – bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer4(11) , 839–849 (2004).
  • De WO , DemetterP, MareelM, BrackeM. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer123(10) , 2229–2238 (2008).
  • Krtolica A , ParrinelloS, LockettS, DesprezPY, CampisiJ. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci.USA98(21) , 12072–12077 (2001).
  • Gonda TA , TuS, WangTC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle.8(13) , 2005–2013 (2009).
  • Kurose K , GilleyK, MatsumotoS, WatsonPH, ZhouXP, EngC. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet.32(3) , 355–357 (2002).
  • Hill R , SongY, CardiffRD, van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell123(6) , 1001–1011 (2005).
  • Hu M , YaoJ, CaiL et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37(8) , 899–905 (2005).
  • Radisky DC , KennyPA, BissellMJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J. Cell. Biochem.101(4) , 830–839 (2007).
  • Zeisberg EM , PotentaS, XieL, ZeisbergM, KalluriR. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res.67(21) , 10123–10128 (2007).
  • Direkze NC , Hodivala-DilkeK, JefferyR et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64(23) , 8492–8495 (2004).
  • Wipff PJ , RifkinDB, MeisterJJ, HinzB. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J. Cell. Biol.179(6) , 1311–1323 (2007).
  • Leask A , AbrahamDJ. TGF-β signaling and the fibrotic response. FASEB J.18(7) , 816–827 (2004).
  • Powell DW , AdegboyegaPA, Di Mari JF, Mifflin RC. Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am. J. Physiol. Gastrointest. Liver Physiol.289(1) , G2–G7 (2005).
  • Ostman A , HeldinCH. PDGF receptors as targets in tumor treatment. Adv. Cancer Res.97 , 247–274 (2007).
  • Spaeth EL , DembinskiJL, SasserAK et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4) , e4992 (2009).
  • Iwano M , PliethD, DanoffTM, XueC, OkadaH, NeilsonEG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest.110(3) , 341–350 (2002).
  • Faouzi S , LeBB, NeaudV et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J. Hepatol. 30(2) , 275–284 (1999).
  • Serini G , Bochaton-PiallatML, RoprazP et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J. Cell. Biol. 142(3) , 873–881 (1998).
  • Chang HY , ChiJT, DudoitS et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99(20) , 12877–12882 (2002).
  • Grugan KD , MillerCG, YaoY et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc. Natl Acad. Sci. USA 107(24) , 11026–11031 (2010).
  • Li G , SatyamoorthyK, HerlynM. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res.61(9) , 3819–3825 (2001).
  • Franco OE , JiangM, StrandDW et al. Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 71(4) , 1272–1281 (2011).
  • Rudnick JA , ArendtLM, KlebbaI et al. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One 6(9) , e24605 (2011).
  • Skobe M , FusenigNE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA95(3) , 1050–1055 (1998).
  • Tjomsland V , SpangeusA, ValilaJ et al. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13(8) , 664–675 (2011).
  • Hugo HJ , LebretS, Tomaskovic-CrookE et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 5(1) , 83–93 (2012).
  • Hynes RO . The extracellular matrix: not just pretty fibrils. Science326(5957) , 1216–1219 (2009).
  • Erez N , TruittM, OlsonP, ArronST, HanahanD. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell17(2) , 135–147 (2010).
  • Orimo A , GuptaPB, SgroiDC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3) , 335–348 (2005).
  • Fukumura D , XavierR, SugiuraT et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6) , 715–725 (1998).
  • Crawford Y , KasmanI, YuL et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1) , 21–34 (2009).
  • Powathil G , KohandelM, MilosevicM, SivaloganathanS. Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies. Comput. Math. Methods Med.2012 , 410602– (2012).
  • Pavlides S , TsirigosA, MignecoG et al. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 9(17) , 3485–3505 (2010).
  • Cannito S , NovoE, CompagnoneA et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29(12) , 2267–2278 (2008).
  • Taub DD , Turcovski-CorralesSM, KeyML, LongoDL, MurphyWJ. Chemokines and T lymphocyte activation: I. β chemokines costimulate human T lymphocyte activation in vitro. J. Immunol.156(6) , 2095–2103 (1996).
  • Sturm A , KrivacicKA, FiocchiC, LevineAD. Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J. Immunol.173(6) , 3889–3900 (2004).
  • Barnas JL , Simpson-AbelsonMR, YokotaSJ, KelleherRJ, BankertRB. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron.3(1) , 29–47 (2010).
  • Liao D , LuoY, MarkowitzD, XiangR, ReisfeldRA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One4(11) , e7965 (2009).
  • Chomarat P , BanchereauJ, DavoustJ, PaluckaAK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol.1(6) , 510–514 (2000).
  • Protti MP , DeML. Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology1(1) , 89–91 (2012).
  • Shojaei F , ZhongC, WuX, YuL, FerraraN. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell. Biol.18(8) , 372–378 (2008).
  • Nizar S , MeyerB, GalustianC, KumarD, DalgleishA. T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta1806(1) , 7–17 (2010).
  • Munn DH , MellorAL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest.117(5) , 1147–1154 (2007).
  • Pinchuk IV , SaadaJI, BeswickEJ et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135(4) , 1228–1237, 1237 (2008).
  • Chen CH , Seguin-DevauxC, BurkeNA et al. Transforming growth factor β blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med. 197(12) , 1689–1699 (2003).
  • Nazareth MR , BroderickL, Simpson-AbelsonMR, KelleherRJ, YokotaSJ, BankertRB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol.178(9) , 5552–5562 (2007).
  • Balsamo M , ScordamagliaF, PietraG et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl Acad. Sci. USA 106(49) , 20847–20852 (2009).
  • Egeblad M , WerbZ. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2(3) , 161–174 (2002).
  • Toullec A , GeraldD, DespouyG et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2(6) , 211–230 (2010).
  • Marastoni S , LigrestiG, LorenzonE, ColombattiA, MongiatM. Extracellular matrix: a matter of life and death. Connect. Tissue Res.49(3) , 203–206 (2008).
  • Kanayama S , YamadaY, KawaguchiR, TsujiY, HarutaS, KobayashiH. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol. Rep.19(1) , 117–122 (2008).
  • Gaggioli C , HooperS, Hidalgo-CarcedoC et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell. Biol. 9(12) , 1392–1400 (2007).
  • Mani SA , GuoW, LiaoMJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4) , 704–715 (2008).
  • Stuelten CH , BuschJI, TangB et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-β mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 5(3) , e9832 (2010).
  • Boyd NF , GuoH, MartinLJ et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 356(3) , 227–236 (2007).
  • Cohen SJ , AlpaughRK, PalazzoI et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37(2) , 154–158 (2008).
  • Shi M , YuDH, ChenY et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 18(8) , 840–846 (2012).
  • Fujita H , OhuchidaK, MizumotoK et al. α-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 39(8) , 1254–1262 (2010).
  • Schoppmann SF , BerghoffA, DinhofC et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat. 134(1) , 237–244 (2012).
  • Spiotto MT , RowleyDA, SchreiberH. Bystander elimination of antigen loss variants in established tumors. Nat. Med.10(3) , 294–298 (2004).
  • Zhang B , BowermanNA, SalamaJK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204(1) , 49–55 (2007).
  • Sethi T , RintoulRC, MooreSM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5(6) , 662–668 (1999).
  • Heldin CH , RubinK, PietrasK, OstmanA. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer4(10) , 806–813 (2004).
  • Brown JM , GiacciaAJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res.58(7) , 1408–1416 (1998).
  • Liang D , MaY, LiuJ et al. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12 , 201– (2012).
  • Fassnacht M , LeeJ, MilazzoC et al. Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 11(15) , 5566–5571 (2005).
  • Ostman A , AugstenM. Cancer-associated fibroblasts and tumor growth – bystanders turning into key players. Curr. Opin. Genet. Dev.19(1) , 67–73 (2009).
  • Rettig WJ , Garin-ChesaP, BeresfordHR, OettgenHF, MelamedMR, OldLJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl Acad. Sci. USA85(9) , 3110–3114 (1988).
  • Rettig WJ , SuSL, FortunatoSR et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer 58(3) , 385–392 (1994).
  • Park JE , LenterMC, ZimmermannRN, Garin-ChesaP, OldLJ, RettigWJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem.274(51) , 36505–36512 (1999).
  • Garin-Chesa P , OldLJ, RettigWJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl Acad. Sci. USA87(18) , 7235–7239 (1990).
  • Kelly T . Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Res. Updat.8(1–2) , 51–58 (2005).
  • Chen WT , KellyT. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev.22(2–3) , 259–269 (2003).
  • Brennen WN , IsaacsJT, DenmeadeSR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther.11(2) , 257–266 (2012).
  • Cheng JD , ValianouM, CanutescuAA et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4(3) , 351–360 (2005).
  • Kraman M , BambroughPJ, ArnoldJN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330(6005) , 827–830 (2010).
  • Santos AM , JungJ, AzizN, KissilJL, PureE. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest.119(12) , 3613–3625 (2009).
  • LeBeau AM , BrennenWN, AggarwalS, DenmeadeSR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther.8(5) , 1378–1386 (2009).
  • Welt S , DivgiCR, ScottAM et al. Antibody targeting in metastatic colon cancer: a Phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12(6) , 1193–1203 (1994).
  • Scott AM , WisemanG, WeltS et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5) , 1639–1647 (2003).
  • Tanswell P , Garin-ChesaP, RettigWJ et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br. J. Clin. Pharmacol. 51(2) , 177–180 (2001).
  • Ostermann E , Garin-ChesaP, HeiderKH et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14(14) , 4584–4592 (2008).
  • Wuest T , GerlachE, BanerjeeD, GerspachJ, MoosmayerD, PfizenmaierK. TNF-selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene21(27) , 4257–4265 (2002).
  • Messerschmidt SK , MusyanovychA, AltvaterM et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J. Control. Release 137(1) , 69–77 (2009).
  • Samel D , MullerD, GerspachJ et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 278(34) , 32077–32082 (2003).
  • Burckhart T , ThielM, NishikawaH et al. Tumor-specific crosslinking of GITR as costimulation for immunotherapy. J. Immunother.33(9) , 925–934 (2010).
  • Lee J , FassnachtM, NairS, BoczkowskiD, GilboaE. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res.65(23) , 11156–11163 (2005).
  • Loeffler M , KrugerJA, NiethammerAG, ReisfeldRA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest.116(7) , 1955–1962 (2006).
  • Wen Y , WangCT, MaTT et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101(11) , 2325–2332 (2010).
  • Sadelain M , RiviereI, BrentjensR. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer3(1) , 35–45 (2003).
  • Kakarla S , WangL, RowleyD, PfizenmaierK, GottschalkS. Improving T-cell immunotherapies for solid tumors by targeting the tumor stroma. Biol. Blood Marrow Trans.17(2 Suppl. 1) , S270 (2011).
  • Kobayashi T , LiuX, WenFQ et al. Smad3 mediates TGF-β1 induction of VEGF production in lung fibroblasts. Biochem. Biophys. Res. Commun. 327(2) , 393–398 (2005).
  • Chen MM , LamA, AbrahamJA, SchreinerGF, JolyAH. CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J. Mol. Cell. Cardiol.32(10) , 1805–1819 (2000).
  • Yingling JM , BlanchardKL, SawyerJS. Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov.3(12) , 1011–1022 (2004).
  • Fakhrai H , DorigoO, ShawlerDL et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl Acad. Sci. USA 93(7) , 2909–2914 (1996).
  • Nemunaitis J , DillmanRO, SchwarzenbergerPO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29) , 4721–4730 (2006).
  • Flechsig P , DadrichM, BickelhauptS et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP associated proinflammatory and proangiogenic signals. Clin. Cancer Res. 18(13) , 3616–3627 (2012).
  • Akhurst RJ . TGF-β antagonists: why suppress a tumor suppressor? J. Clin. Invest.109(12) , 1533–1536 (2002).
  • Akhurst RJ . TGF β signaling in health and disease. Nat. Genet.36(8) , 790–792 (2004).
  • Bollard CM , RossigC, CalongeMJ et al. Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 99(9) , 3179–3187 (2002).
  • Lacuesta K , BuzaE, HauserH et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-β receptor. J. Immun. 29(3) , 250–260 (2006).
  • Yu Q , StamenkovicI. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev.14(2) , 163–176 (2000).
  • Hidalgo M , EckhardtSG. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst.93(3) , 178–193 (2001).
  • Steeghs N , NortierJW, GelderblomH. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol.14(2) , 942–953 (2007).
  • Escudier B , EisenT, StadlerWM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2) , 125–134 (2007).
  • Vanneman M , DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer12(4) , 237–251 (2012).
  • Shrimali RK , YuZ, TheoretMR, ChinnasamyD, RestifoNP, RosenbergSA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res.70(15) , 6171–6180 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.